Tvardi Therapeutics
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Sugar Creek Center Blvd Ste 525, Sugar...Phone Number
(713) 489-8654Website
www.tvarditherapeutics.comRevenue
-Stock Symbol
TVRDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, USA, focused on developing a new class of breakthrough medicines for fibrosis-driven diseases. Founded in 2017, the company is led by a team of experienced entrepreneurs, innovative scientists, and dedicated physicians committed to advancing novel therapies that address significant unmet medical needs. Operating in the Biotechnology / Pharmaceutical Research industry, Tvardi Therapeutics leverages cutting-edge science and clinical expertise to discover and develop therapies that inhibit key disease pathways, aiming to improve patient outcomes and reduce the societal and economic impact of fibrosis-related conditions. The company conducts clinical trials to evaluate the safety and efficacy of its therapeutics and is dedicated to translating scientific innovation into meaningful treatments for patients worldwide.Explore more
Tvardi Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tvardi Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Tvardi Therapeutics
Check if Tvardi Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Tvardi Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Tvardi Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tvardi Therapeutics launches new products
Tvardi Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Tvardi Therapeutics had a recent Job posting/layoffs
Check out if Tvardi Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Tvardi Therapeutics
Compare insights from companies similar to Tvardi Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tvardi Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tvardi Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tvardi Therapeutics.
Tvardi Therapeutics financials insights
Gather financial insights about Tvardi Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$9M
2020
Grant
$5M
2021
Series B
$74M
Tvardi Therapeutics Tech Stack
A closer look at the technologies used by Tvardi Therapeutics
See more technologies
Most Recent Scoops
Project
Tvardi Therapeutics has advanced TTI-109, its next-generation STAT3 inhibitor and phosphate prodrug of its first-generation molecule, demonstrating that the compound meets its design objectives with rapid conversion, predictable dose-proportional pharmacokinetics, improved gastrointestinal tolerability, and pharmacodynamic reductions in disease-associated immune populations, including T cells and B cells, in healthy volunteers.
Medical Research, Pharmaceuticals
Project
Tvardi Therapeutics has completed 9-month monkey toxicology studies for TTI-109 with no additional preclinical experiments anticipated, and expects to file an Investigational New Drug (IND) application for a Phase II program in one or both target indications by year-end, with a study initiation possible in H1 of next year.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Tvardi Therapeutics has reported that the human clinical study of TTI-109 demonstrated a favorable overall safety profile, with treatment-emergent adverse event incidences broadly similar across placebo, TTI-109, and TTI-101 groups, no serious adverse events, no dose-dependent adverse event pattern, and no clinically relevant changes in vital signs or ECGs.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Tvardi Therapeutics has reported that its STAT3 inhibitor program demonstrates at least a four-to-one plasma-to-disease-tissue drug concentration ratio, with target-dependent engagement confirmed, and does not anticipate requiring doses above the recommended Phase II dose of TTI-101 (400 mg twice daily), equivalent to 500 mg twice daily of TTI-109.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Tvardi Therapeutics News & Media
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wednesday, August 19, 2026 at 11:00 AM ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodelingTvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement July 7,...Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tvardi Therapeutics
Sign Up For FreeTo access detailed company insights
Tvardi Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, USA, focused on developing a new class of breakthrough medicines for fibrosis-driven diseases. Founded in 2017, the company is led by a team of experienced entrepreneurs, innovative scientists, and dedicated physicians committed to advancing novel therapies... Read More
